Zambon expands in Europe acquiring Nigaard

20 July 2015

Italy-based CNS specialist Zambon says it has acquired Nigaard, a full service specialized company headquartered in Oslo, Norway. Financial terms of the transaction were not disclosed.

Established in 2002, Nigaard is a licensed pharmaceutical company focused on respiratory and allergy, including pharmaceuticals and medical devices, well developed in all the countries of Northern Europe: Denmark, Norway, Sweden, Iceland and Finland. It is currently Promixin(colistin) distributor for Sweden and Norway, as well as owner of several distribution and licensing agreements.

Promixin is a drug that came to Zambon along with its acquisition of UK drugmaker Profile Pharma. With the acquisition of Nigaard, that follows the Profile Pharma deal and the re-establishment of a branch in Germany in 2014, Zambon is now covering all the Western Europe markets, the company stated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK